← Evidence map

ReviewBiologics : targets & therapy2018

Two decades with omalizumab: what we still have to learn.

Cristoforo Incorvaia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

15 papers cite it

2018
2019
2020
2021
2022
2023
2024
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 30464389